Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a
new class of drugs based on targeted protein degradation, announced
it will present preclinical data from its tau-targeted PROTAC®
protein degrader program at the Alzheimer's Association
International Conference (AAIC®), held July 14-18, 2019, in Los
Angeles, California. Angela Cacace, Ph.D., Vice President of
Neuroscience and Platform Biology at Arvinas, was selected to chair
the session entitled, Molecular and Cell Biology: Tau Biology,
Aggregation and Spreading. In this session, Dr. Cacace will give an
oral presentation entitled “A New Therapeutic Strategy for
Tauopathies - Discovery of Highly Potent Brain-Penetrant PROTAC®
Degrader Molecules That Target Pathologic Tau Protein Species.”
This presentation will also discuss Arvinas’ strategy in creating
PROTAC® targeted protein degraders for neurological disorders.
The preclinical studies show a tau-targeted PROTAC®
protein degrader eliminated more than 95% of disease-causing
(pathologic) tau protein in the brain of a well-characterized mouse
tauopathy model, following parenteral (peripheral) administration.
The data further indicate that the tau protein degradation is dose
and concentration dependent, signifying the tau-targeted PROTAC®
protein degrader molecule effectively crosses the blood brain
barrier.
“These data indicate the potential for PROTAC®
protein degraders in diseases of the central nervous system,
reinforcing our belief that there are many indications, including
previously ‘undruggable’ targets, for which our technology may be
advantageous,” said Dr. Cacace. “The fact that these degraders have
both crossed the blood-brain barrier, and specifically degraded
pathologic tau, increases our conviction and excitement in moving
additional PROTAC® protein degrader programs forward in
neuroscience.”
Tau has been implicated in several neurological
disorders, including Alzheimer’s disease. At AAIC, Dr. Cacace will
detail Arvinas’ strategy in neuroscience, which will include
initially pursuing indications that are “pure” tauopathies, such as
progressive supranuclear palsy (PSP) and genetic tauopathies, such
as frontotemporal dementia with parkinsonism-17 (FTDP-17), to prove
the effectiveness of tau-directed PROTAC® protein degraders.
Arvinas has additional preclinical neuroscience programs, including
alpha-synuclein (implicated in Parkinson’s disease), as well as a
robust, clinical-stage oncology pipeline.
AAIC® is the premier and largest international
meeting focused on advancing Alzheimer’s and dementia science. The
annual conference convenes the world's leading basic science and
clinical researchers, next-generation investigators, clinicians and
the care research community to share research discoveries
supporting new methods of prevention, treatment and diagnosis of
Alzheimer's disease.
Presentation Details:
- Session Title: Molecular and Cell Biology: Tau Biology,
Aggregation and Spreading
- Talk Title: A New Therapeutic Strategy for Tauopathies -
Discovery of Highly Potent Brain-Penetrant PROTAC® Degrader
Molecules That Target Pathologic Tau Protein Species
- Date and Time: Thursday, July 18, 2019 at 12:45pm PT
- Location: Los Angeles Convention Center, Petree Hall D
About PROTAC® Protein
DegradersArvinas’ PROTAC® protein degraders harness the
body’s own natural protein disposal system to degrade
disease-causing proteins. PROTAC® protein degraders recruit an E3
ligase to tag the target protein with ubiquitin, which directs its
degradation through the proteasome, a large protein complex that
breaks down the ubiquitinated target protein into small peptides
and amino acids. As the target protein is degraded, the PROTAC®
protein degrader is released and acts iteratively to destroy
additional target protein.
PROTAC® protein degraders offer numerous potential
advantages as a therapeutic, including broad tissue distribution
(including the ability to design for blood brain barrier
penetration), routes of administration that include oral delivery,
and simpler manufacturing than other new modalities, such as
cell-based therapies. Arvinas has developed and optimized a
proprietary library of protein targeting ligands, E3 ligase
ligands, and linkers, which allow the company to rapidly identify
and optimize efficient protein degraders with favorable
characteristics for successful drug development.
About Arvinas Arvinas is
a clinical-stage biopharmaceutical company dedicated to improving
the lives of patients suffering from debilitating and
life-threatening diseases through the discovery, development, and
commercialization of therapies that degrade disease-causing
proteins. Arvinas uses its proprietary technology
platform to engineer proteolysis targeting chimeras, or PROTAC®
targeted protein degraders, that are designed to harness the body’s
own natural protein disposal system to selectively and efficiently
degrade and remove disease-causing proteins. The company’s lead
program, ARV-110 for the treatment of patients with metastatic
castrate-resistant prostate cancer, began a Phase 1 clinical trial
in the first quarter of 2019. For more information,
visit www.arvinas.com.
Forward-Looking Statements This
press release contains forward-looking statements that involve
substantial risks and uncertainties, including statements regarding
the development, regulatory status and therapeutic potential of our
investigational product candidates. All statements, other than
statements of historical facts, contained in this press release,
including statements regarding our strategy, future operations,
prospects, plans and objectives of management, are forward-looking
statements. The words “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,”
“target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
We may not actually achieve the plans, intentions
or expectations disclosed in our forward-looking statements, and
you should not place undue reliance on our forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements we make as a result of various risks and
uncertainties including but not limited to the important factors
discussed in the “Risk Factors” sections contained in our quarterly
and annual reports on file with the Securities and Exchange
Commission. The forward-looking statements contained in this press
release reflect our current views with respect to future events,
and we assume no obligation to update any forward-looking
statements except as required by applicable law. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this release.
Contacts for Arvinas
InvestorsWill O’Connor, Stern
Investor Relationsir@arvinas.com
MediaCory Tromblee,
ScientPRpr@arvinas.com
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arvinas (NASDAQ:ARVN)
Historical Stock Chart
From Apr 2023 to Apr 2024